130 related articles for article (PubMed ID: 38745448)
1. Economic burden of generalized myasthenia gravis (MG) in the United States and the impact of common comorbidities and acute MG-events.
Zhdanava M; Pesa J; Boonmak P; Cai Q; Pilon D; Choudhry Z; Souayah N
Curr Med Res Opin; 2024 May; ():1-9. PubMed ID: 38745448
[TBL] [Abstract][Full Text] [Related]
2. Real-World Healthcare Resource Utilization and Cost Burden Assessment for Adults With Generalized Myasthenia Gravis in the United States.
Phillips G; Abreu C; Goyal A; Li Y; Whangbo A; Gelinas D; Brauer E; Bhattacharya S
Front Neurol; 2021; 12():809999. PubMed ID: 35115997
[TBL] [Abstract][Full Text] [Related]
3. Healthcare resource utilization and costs associated with generalized myasthenia gravis: a retrospective matched cohort study using the National Health Insurance Research Database in Taiwan.
Shen SP; Herr KJ; Liu Y; Yang CC; Tang CH
Front Neurol; 2023; 14():1216595. PubMed ID: 37564734
[TBL] [Abstract][Full Text] [Related]
4. Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United States.
Jain SS; Li SS; Xie J; Sutton MB; Fine JT; Edelberg JM; Gao W; Spertus JA; Cohen DJ
J Med Econ; 2021; 24(1):1115-1123. PubMed ID: 34493144
[TBL] [Abstract][Full Text] [Related]
5. Excess healthcare resource utilization and healthcare costs among privately and publicly insured patients with major depressive disorder and acute suicidal ideation or behavior in the United States.
Zhdanava M; Voelker J; Pilon D; Joshi K; Morrison L; Sheehan JJ; Vermette-Laforme M; Lefebvre P; Citrome L
J Affect Disord; 2022 Aug; 311():303-310. PubMed ID: 35597466
[TBL] [Abstract][Full Text] [Related]
6. Impact of benralizumab on asthma exacerbation-related medical healthcare resource utilization and medical costs: results from the ZEPHYR 2 study.
Chung Y; Maselli DJ; Mu F; Cook EE; Yang D; Young JA; Betts KA; Genofre E; Carstens D
J Med Econ; 2023; 26(1):954-962. PubMed ID: 37441729
[TBL] [Abstract][Full Text] [Related]
7. Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data.
Pisc J; Ting A; Skornicki M; Sinno O; Lee E
J Comp Eff Res; 2024 Jan; 13(1):e230108. PubMed ID: 38099519
[No Abstract] [Full Text] [Related]
8. Health care resource utilization and costs associated with psychiatric comorbidities in adult patients with attention-deficit/hyperactivity disorder.
Schein J; Cloutier M; Gauthier-Loiselle M; Bungay R; Chen K; Chan D; Childress A
J Manag Care Spec Pharm; 2024 Jun; 30(6):588-598. PubMed ID: 38824634
[TBL] [Abstract][Full Text] [Related]
9. Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database.
Bhowmik D; Hines DM; Intorcia M; Wade RL
J Med Econ; 2018 Jun; 21(6):622-628. PubMed ID: 29571273
[TBL] [Abstract][Full Text] [Related]
10. Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Diabetes.
Weir MR; Chen YW; He J; Bookhart B; Campbell A; Ashton V
Diabetes Ther; 2021 Dec; 12(12):3167-3186. PubMed ID: 34699020
[TBL] [Abstract][Full Text] [Related]
11. Burden of Herpes Zoster Among Patients with Psoriatic Arthritis in the United States.
Singer D; Thompson-Leduc P; Ma S; Gupta D; Cheng WY; Sendhil SR; Sundar M; Hagopian E; Stempniewicz N; Duh MS; Poston S
Psoriasis (Auckl); 2024; 14():63-78. PubMed ID: 38939905
[TBL] [Abstract][Full Text] [Related]
12. Economic Burden of Commercially Insured Patients With Major Depressive Disorder and Acute Suicidal Ideation or Behavior in the United States.
Pilon D; Neslusan C; Zhdanava M; Sheehan JJ; Joshi K; Morrison L; Rossi C; Lefebvre P; Greenberg PE
J Clin Psychiatry; 2022 Apr; 83(3):. PubMed ID: 35390231
[No Abstract] [Full Text] [Related]
13. Real-World Evaluation of Direct and Indirect Economic Burden Among Endometriosis Patients in the United States.
Soliman AM; Surrey E; Bonafede M; Nelson JK; Castelli-Haley J
Adv Ther; 2018 Mar; 35(3):408-423. PubMed ID: 29450864
[TBL] [Abstract][Full Text] [Related]
14. Understanding the Symptom Burden and Impact of Myasthenia Gravis from the Patient's Perspective: A Qualitative Study.
Jackson K; Parthan A; Lauher-Charest M; Broderick L; Law N; Barnett C
Neurol Ther; 2023 Feb; 12(1):107-128. PubMed ID: 36322146
[TBL] [Abstract][Full Text] [Related]
15. Comparative Assessment of Medical Resource Use and Costs Associated with Patients with Symptomatic Peripheral Artery Disease in the United States.
Chase MR; Friedman HS; Navaratnam P; Heithoff K; Simpson RJ
J Manag Care Spec Pharm; 2016 Jun; 22(6):667-75. PubMed ID: 27231794
[TBL] [Abstract][Full Text] [Related]
16. Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate.
Patel C; Emond B; Lafeuille MH; Côté-Sergent A; Lefebvre P; Tandon N; El Khoury AC
Drugs Real World Outcomes; 2020 Mar; 7(1):19-29. PubMed ID: 31786737
[TBL] [Abstract][Full Text] [Related]
17. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
[TBL] [Abstract][Full Text] [Related]
18. Economic burden in Medicaid beneficiaries with recently relapsed schizophrenia or with uncontrolled symptoms of schizophrenia not adherent to antipsychotics.
Pilon D; Patel C; Lafeuille MH; Zhdanava M; Lin D; Côté-Sergent A; Rossi C; Lefebvre P; Joshi K
J Manag Care Spec Pharm; 2021 Jul; 27(7):904-914. PubMed ID: 34185557
[No Abstract] [Full Text] [Related]
19. Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States.
Zhdanava M; Teeple A; Pilon D; Shah A; Caron-Lapointe G; Joshi K
J Med Econ; 2023; 26(1):691-700. PubMed ID: 37130075
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
